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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A45KOmice showed reduced expression of MMPs. This correlates well with
our ﬁnding that stimulation of human OA synovium with WISP1 led to
increased MMP expression. TGF-b signaling via Smad 2/3 is crucial for
maintaining the homeostasis of the cartilage, while signaling via Smad
1/5/8 is associated with chondrocyte hypertrophy. In order to deter-
mine if WISP1 affects TGF-b signaling, we stained WT and WISP1
depleted joints for phosphorylated Smad 2/3. We found that Smad 2/3
signaling was increased in the WISP1 KO mice, suggesting that
increasedWISP1 expression during OA decreases Smad 2/3 signaling. In
addition, recent data showed that WISP1 might not only act as a
downstream target of canonical Wnt signaling, but could also regulate
the accumulation of b-catenin, and positively control canonical Wnt
signaling, further aggravating the OA pathology. To investigate if this
mechanismwas present in experimental OA, we stained our sections for
b-catenin and found thatWISP1 depleted tissues indeed have decreased
levels of b-catenin accumulation in the cartilage.
Conclusions: Overexpression of WISP1 in the synovium and cartilage,
as is found in OA conditions, may play an important role in OA path-
ology via modulation of TGF-b signaling and via a positive feedback
mechanism on canonical Wnt signaling. Because Wnt signaling is both
extremely complex and tightly regulated and can affect many biological
processes, upstream targeting of Wnt signaling is likely to produce
undesired side-effects. Speciﬁc downregulation of WISP1 may more
speciﬁcally target the pathological events that take place during OA
without interfering with normal processes.
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Purpose: Several population studies have found an association between
increased body mass index (BMI), as a measure of obesity, and higher
disc degeneration scores and that the effect of obesity upon back pain is
mediated by greater disc degeneration. However, other pathological
changes to the disc and spinal column, in particular disc herniation and
spinal stenosis, are associated with speciﬁc clinical conditions; whether
these pathological changes are also inﬂuenced by obesity is unclear.
Here we examine the relationships between BMI and MRI measures of
intervertebral disc degeneration (DD), disc herniation (DH) and spinal
stenosis (SS), using a large prospectively recruited patient population.
Methods: Patients were recruited from tertiary spine centres in 4 EU
countries. An experienced radiologist scored T1 and T2 magnetic res-
onance images (MRI) images for DD (Pﬁrrmann grading system), any
DH (size and presence) or any SS (presence and severity). Multivariate
linear and logistic regression analyses were used to model the rela-
tionship between these variables and BMI. Given the comprehensive
data collection, we were able to adjust for both patient (age, gender,
sporting activity, smoking, occupation and comorbidities) and MRI
deﬁned (Modic changes, end plate sclerosis and end plate defects)
confounders.
Results: The analysis included 1684 patients with a mean age of 51
years and BMI of 27.2kg/m2. The relationship between age and DD
(r¼0.66) was considerably stronger than that for BMI and DD (r¼0.17)
(Figure a & b). Lumbar disc degeneration and disc herniation were
both more marked at lower spinal levels with L5/S1 showing the
highest DD and greatest prevalence of DH. In the fully adjusted model,
a 10-year increase in age and a 5kg/m2 increase in BMI were asso-
ciated with a 0.31 unit [CI 0.29,0.34] and 0.04 unit [CI 0.01,0.07]
increase in degeneration, respectively. BMI was not associated with
severe (grade 5) DD (OR 1.06 [CI 0.94,1.20]) or multilevel DD (OR 1.12
[CI 0.96,1.30]). All end plate features were associated with more severe
degeneration. Age (OR 2.60 [CI 2.28,2.96]) and BMI (OR 1.23 [CI
1.06,1.43]) were also positively associated with the presence of
stenosis. BMI was also a positive predictor of multilevel stenosis (OR
1.18 [CI 1.00,1.39]) but not severe stenosis (OR 1.11 [CI 0.92,1.35]). In
contrast, BMI was not a predictor of multilevel herniation (OR 1.14 [CI
0.97,1.35]) but was for severe herniation (OR 1.13 [CI 1.01,1.27]). For DHpresence, age was a negative predictor (OR 0.70 [CI 0.64,0.76]) but BMI
(OR 1.19 [CI 1.07,1.33]) showed a strong positive association. There
were no other signiﬁcant predictors of either DH or SS. When the
upper lumbar spine was considered separately, BMI was the strongest
predictor for disc herniation (OR 1.39 [CI 1.10,1.77]) and spinal stenosis
(OR 1.65 [CI 1.27,2.16]).
Conclusions: An increase in disc degeneration was most strongly
associated with increasing age. Increasing age was also a strong pre-
dictor of spinal stenosis and, after mid-life, a negative predictor for disc
herniation. Higher body mass index was associated with greater disc
degeneration but the small coefﬁcient suggests limited clinical rele-
vance. The upper lumbar discs appear more sensitive to increased BMI,
supporting the upper lumbar spine phenotype described by others.
Abnormal loading in obesity could be a mediator of this. For disc her-
niation and spinal stenosis, BMI is a more clinically meaningful positive
predictor than for disc degeneration. We now need to understand how
obesity predisposes to DH and SS and if weight loss can help prevent
these conditions.
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Purpose: OA and associated joint pain is a major cause of disability,
and there is a high unmet need for effective and safe analgesic
therapies. Substantial pain alleviation has been reported for OA
patients treated with intravenous (IV) infusions of antibodies which
block nerve growth factor (NGF), however an increased drug-related
risk for accelerated OA progression was observed in some patients. As
an alternate strategy for targeting this pathway, we identiﬁed a novel
small molecule compound, GZ389988, as an inhibitor of TrkA, the
high-afﬁnity receptor for NGF. GZ389988 was formulated for intra-
articular (IA) delivery, and its effects on local knee pain were tested in
rats using both a monosodium iodoacetate (MIA) induced model of OA,
as well as an arthritis ﬂare model mediated by streptococcal pepti-
doglycan polysaccharide (PGPS).
Methods: Identiﬁcation of TrkA inhibitor GZ389988: Drug candidate
screening was conducted to select inhibitors of Trk family tyrosine
kinases. Low solubility compounds were evaluated using a cell-based
TrkA assay, and further screened against kinase and safety/liability
panels. Acute cytotoxicity was assessed by neutral red assay for a variety
of cell types, including primary human chondrocytes and synoviocytes
(Articular Engineering). In vivo biocompatibility was tested by IA
injection of GZ389988 into rat knee joints.
Preclinical rat OA model: Unilateral knee OA was initiated by IA
injection of MIA. One week later, diseased (ipsilateral) joints were
treated with a single IA injection of GZ389988 or placebo/vehicle, and
differences in hind-limb weight distribution were measured weekly
for 4 weeks by incapacitance testing. In some cases, GZ389988 was
administered to the contralateral knee instead, to test for the occur-
rence of systemic compound distribution affecting the ipsilateral
joint.
Preclinical rat arthritis ﬂaremodel (Bolder BioPATH): Unilateral primary
knee arthritis was induced by IA injection of PGPS. Two weeks later,
animals received a single IA injection of GZ389988 or placebo/vehicle
into the diseased (ipsilateral) joint. Disease reactivation ﬂares were
triggered by IV administration of PGPS at weeks 1 and 3 following drug
(or placebo) treatment. Gait analysis was conducted by obtaining inked
pawprint impressions from animals which were allowed to ambulate
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performed using 4 distinct pawprint pairs per animal, collected daily for
4 days following each reactivation.
Results: GZ389988 was identiﬁed as a potent inhibitor of TrkA (similar
IC50 values observed for TrkA, TrkB, TrkC and cFMS/CSF1R), with a high
level of selectivity against a wide panel of other kinases. In addition,
GZ389988 has very low aqueous solubility, thus facilitating its for-
mulation for local administration. No cytotoxicity was observed in cell-
based assays using criteria of LD50/IC50 ratio >100. In vivo bio-
compatibility studies with GZ389988 showed neither a treatment effect
on body weight or clinical appearance, nor any signiﬁcant histopatho-
logic changes in joint tissues.
In the rat MIA model, a single ipsilateral dose of GZ389988 provided a
signiﬁcant reduction in local joint pain (weight-bearing imbalance) for
4 weeks. Treatment of the contralateral joint with GZ389988 had no
effect on ipsilateral joint pain (Fig. 1), illustrating the absence of a
substantial systemic effect following IA administration. GZ389988 was
also efﬁcacious in the PGPS arthritis model, demonstrating a signiﬁcant
improvement of gait analysis scores following painful disease reac-
tivation ﬂares (Fig. 2).
Conclusions: Elevated levels of NGF are associated with tissue injury,
and have been observed in a number of painful conditions including OA.
In addition, TrkA is expressed by OA synovial ﬁbroblasts and is upre-
gulated in response to NGF. In OA pain trials, NGF-blocking Abs have
demonstrated signiﬁcant efﬁcacy with high patient responder rates,
however such studies have been subject to clinical hold by the FDA due
to the occurrence of joint-related adverse events. We have targeted the
NGF pain signaling pathway using a locally-effective inhibitor of TrkA.
In addition to the efﬁcacy data presented here, pharmacokinetic studies
and safety pharmacology and preclinical toxicology data support the
development of GZ389988 as a novel therapeutic approach for the
treatment of OA and joint pain.
Figure 1. Efﬁcacy of GZ389988 in rat MIA model of joint pain. Disease was
initiated by a single IA injection of MIA into the knee joint (ipsilateral).
One week later, a single dose of GZ389988 was administered by IA
injection into the ipsilateral or contralateral knee. Differences in hind limb
weight-bearing distribution were measured immediately prior to injec-
tion of MIA (baseline; BL) and GZ389988 (Time 0), and weekly thereafter
for 4 weeks. Data are presented as mean þ SEM.
Figure 2. Efﬁcacy of GZ389988 in rat PGPS model of joint pain. Disease
was inititated by a single IA injection of PGPS into the knee joint (ipsi-
lateral) three weeks prior to the ﬁrst reactivation. A single dose of
GZ389988 was administered by IA injection into the knee one week prior
to the ﬁrst reactivation. Disease reactivation (painful ﬂare) was induccd on
study days 0 and 14 by IV administration of PGPS. Gait analysis was
performed based on pawprint areas, and scored as follows: 1¼ mild
limping/pain; 2¼moderate limping/pain; 3¼marked limping/pain;
4¼severe hopping/pain. Data are presented as mean þ SEM.37
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Purpose: Current pharmacological treatment of hand osteoarthritis
(hand OA) is limited. Treatment options consist of the use of analge-
sics, such as paracetamol or (topical) non-steroidal anti-inﬂammatory
drugs (NSAIDs) and corticosteroids. Although these medications can
provide some relief for patients with mild joint pain, their effect is
temporary and mostly insufﬁcient for patients with more severe
symptoms. Furthermore, chronic use of NSAIDs and corticosteroids is
not recommended because of its potential (serious) side effects.
Hydroxychloroquine (HCQ) has been used successfully in the treat-
ment of mild rheumatoid arthritis and other auto-immune diseases
for many years. The suppression of inﬂammation by inhibition of
cytokines is believed to be part of the mechanism of action. Pain in
hand OA is associated with inﬂammation as well; therefore HCQ
might also be beneﬁcial in hand OA. So far there has only been a few
poor quality retrospective trials that have proven some beneﬁcial
effect of HCQ in hand OA. This is the ﬁrst randomized, double-blind,
placebo-controlled trial to study the symptom modifying effect of HCQ
in hand OA.
Methods: Patients were recruited from outpatient rheumatology clinics
from 6 different hospitals, including one university medical center, in
and around Rotterdam (the Netherlands). Patients,  40 years of age,
with primary hand OA according to the ACR classiﬁcation criteria were
included. Patients with  1 hand joint with a Kellgren and Lawrence
grade 4 were excluded. Hand pain symptoms, independent of level of
severity, had to be present for at least one year. Patients were randomly
assigned to receive either HCQ 400 mg once a day or placebo during a
treatment period of 24 weeks. Paracetamol was used as rescue medi-
cation and patients were allowed to continue all comedication except
NSAIDs during the study. If patients were using NSAIDs, inclusion was
allowed after a wash out period of 1 week. The primary outcome was
decrease of hand pain in the previous 24 hours on a 100 mm visual
analogue scale (VAS) at the end of the study. Secondary outcomes
included change in total score of the Australian Canadian Hand Osteo-
arthritis Index (AUSCAN) and the Arthritis Impact Measurement Scale 2
SF (AIMS2-SF) at the end of the study. Friedman test is used for the
analysis of non-normally distributed data (VAS pain). Repeated meas-
ures ANOVA was used for the normally distributed data (AUSCAN en
AIMS2-SF scores). Multiple imputation (50 imputations) was used to
impute all missing data. Intention to treat analyses were performed in
SPSS v20.0.
Results: Two hundred and two patients were included from July 2010
till December 2013. Six patients who were lost to follow up at an early
stage of the study (i.e. no data at any time point), were excluded from
the analysis. An intention to treat analysis was performed on the
remaining 196 patients (HCQ n ¼ 98, placebo n ¼ 98). No differences
were seen in baseline characteristics between the groups: 86% of the
patients were female, the mean age was 57 years. Twenty-one patients
in the HCQ group and 8 patients in the placebo group discontinued
study medication before 24 weeks. The most reported reasons were
adverse drug events and lack of efﬁcacy. At baseline the median (25th
-75th percentile) VAS pain was 45 mm (26-60) in the HCQ group and
50 mm (25-63) in the placebo group. The mean (SD) total AUSCAN
score was 5.2 (1.9) in the HCQ group and 5.0 (1.9) in the placebo group
(0 - 10 scale). The mean (SD) total AIMS2-SF score was 3.7 (1.2) in the
HCQ group and 3.9 (1.2) group (0 - 10 scale). After 24 weeks the
median (25th -75th percentile) VAS pain was 36 mm (16-58) and 48
mm (23-62) in the HCQ and placebo groups respectively. The
decreases in pain were not statistically signiﬁcant within the groups.
Also, no statistically signiﬁcant difference was seen between the
intervention and placebo group at any time point (t ¼ 0, 6, 12, 24
weeks) for VAS pain scores, AUSCAN total and subscales or AIMS-SF2
outcomes.
Conclusions: This study shows that 24 weeks of treatment with HCQ in
symptomatic hand OA did not reduce pain when compared to placebo.
Also, no effect was observed in change of AUSCAN total and subscales
scores or AIMS2-SF scores between both treatment groups. These
results suggest that HCQ should not be prescribed in patients with
